sublingual delivery glp-1 receptor agonists Schematic illustration of monoagonists, dual and triple Compounding pharmacies for sublingual GLP-1

Newer pharmacologic treatments in adults with type 2 diabetes: A clinical guideline from the American College of Physicians

KFFs analysis of newly released Medicare Part D spending data from CMS shows that total gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss Ozempic, Rybelsus, and Mounjaro has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022 (Figure 1)

These treatments mimic the effects of GLP-1, helping patients manage their weight effectively

Yet subsequent large-scale trials such as REWIND (dulaglutide) and LEADER (liraglutide) did not replicate this signal

The observed weight loss was less than in the SURMOUNT-1 trial, but still significant

Theres also a noted risk for thyroid cancer